Donald Calebaugh, MD in Pleasant Point, ME - Medicare Internal Medicine

Donald Calebaugh, MD is a medicare enrolled "Internal Medicine - Gastroenterology" physician in Pleasant Point, Maine. His current practice location is 11 Back Rd, Pleasant Point, Maine. You can reach out to his office (for appointments etc.) via phone at (207) 853-0644.

Donald Calebaugh is licensed to practice in New York (license number 223214) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1598766404.

Contact Information

	Donald Calebaugh, MD
	11 Back Rd, Pleasant Point, ME 04667-4119
	(207) 853-0644
	(207) 853-6230

Physician's Profile

Full Name	Donald Calebaugh
Gender	Male
Speciality	Internal Medicine - Gastroenterology
Location	11 Back Rd, Pleasant Point, Maine
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1598766404
Provider Enumeration Date: 08/02/2005
Last Update Date: 03/07/2013

Medicare PECOS Information:

PECOS PAC ID: 6901123934
Enrollment ID: I20150331001862

Medical Identifiers

Medical identifiers for Donald Calebaugh such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1598766404	NPI	-	NPPES
02194338	Medicaid	NY

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RG0100X	Internal Medicine - Gastroenterology	223214 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Donald Calebaugh is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Donald Calebaugh, MD Po Box 351, Perry, ME 04667-0351 Ph: (207) 853-0644	Donald Calebaugh, MD 11 Back Rd, Pleasant Point, ME 04667-4119 Ph: (207) 853-0644

News Archive

Smoking belies milder disease but worse prognosis for idiopathic pulmonary fibrosis patients

Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London.

Prometheus announces novel method for early detection of HACA during infliximab treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

Protein C levels help predict severity of illness and risk of death in ICU patients

A simple laboratory test to measure protein C - a natural anti-blood-clotting substance that also reflects the level of inflammation in the body - may offer a useful new indicator of the severity of illness and risk of death among critically ill patients.

Donald Calebaugh, MD - Medicare Internal Medicine in Pleasant Point, ME